Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In September 2014, a proprietary formulation of naltrexone extended-release (ER) plus bupropion-ER (brand name Contrave) was approved by the US Food and Drug Administration (FDA),1 becoming the fourth medication approved for long-term weight management in patients with obesity.2 Liraglutide (brand name Saxenda), a glucagon-like peptide 1 receptor agonist, was also approved for obesity treatment in December 2014. This Viewpoint discusses naltrexone-bupropion ER and its potential use for the adjunctive treatment of patients with obesity.
Yanovski SZ, Yanovski JA. Naltrexone Extended-Release Plus Bupropion Extended-Release for Treatment of Obesity. JAMA. 2015;313(12):1213–1214. doi:10.1001/jama.2015.1617
Customize your JAMA Network experience by selecting one or more topics from the list below.